Pharmaceuticals News and Research

RSS

SSRI's increase risk of abnormal bleeding

New users of selective serotonin reuptake inhibitors (SSRIs, a type of antidepressant) have an increased risk of being admitted to the hospital for abnormal bleeding, according to an article in the November 22 issue of The Archives of Internal Medicine.

23 Nov 2004

Hetero Drugs withdraws antiretrovirals

Following an inspection by the World Health Organization (WHO), generic manufacturer Hetero Drugs Limited, in Hyderbad, India, is withdrawing six antiretrovirals from the WHO prequalification list in order to review data on their bioequivalence.

20 Nov 2004

FDA approves Tarceva (erlotinib)

OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

20 Nov 2004

Transcranial Magnetic Stimulation to treat major depression

Psychiatrists at Rush University Medical Center are testing a noninvasive technique that uses repeated short bursts of magnetic energy to stimulate nerve cells in the brain to treat major depression.

20 Nov 2004

Capsules may be effective in treating bipolar disorder

University of North Carolina at Chapel Hill researchers have announced study results finding that a formulation of three-beaded extended-release carbamazepine capsules (ERC-CBZ) was effective, safe and tolerable in the treatment of bipolar I disorder

19 Nov 2004

FDA Vioxx fiasco raises questions about AIDS drug approvals for developing world

AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.

19 Nov 2004

Biotoxin from puffer fish may provide treatment for opioid withdrawal

On November 10, 2004 investigators involved in a Phase IIa clinical trial of the novel biotoxin Tetrodotoxin (TTX) for the treatment of opioid withdrawal enrolled their first participants.

18 Nov 2004

New antidotes for organophosphates are needed to prepare for chemical attacks in the West

Organophosphates are a group of organic compounds containing phosphorus, some of which are used as pesticides. Organophosphates have also been used in chemical weapons and nerve gas attacks, such as the sarin attack in Japan.

18 Nov 2004

Children throughout the world are increasingly being prescribed antidepressants

Children throughout the world are increasingly being prescribed antidepressants and other drugs designed to calm or stimulate the brain, finds research in Archives of Disease in Childhood. Prescription rates increased the most in the UK, the research suggests.

17 Nov 2004

FDA commits to use of radio frequency identification (RFID) technology

The U.S. Food and Drug Administration (FDA) is stepping up its efforts to improve the safety and security of the nation's drug supply through the use of radio frequency identification (RFID) technology.

16 Nov 2004

Sildenafil tablets will soon have small radio frequency tags

In an effort to combat drug counterfeiting and protect patients, Pfizer has announced a new initiative to use radio frequency identification (RFID) tags that will enable wholesalers and pharmacies to authenticate all Viagra sold in the United States.

16 Nov 2004

World’s strongest acid may have a role in synthesizing pharmaceuticals

Researchers at the University of California, Riverside have discovered the world’s strongest acid. Remarkably it is also the gentlest acid. This non-toxic and non-corrosive acid may have a role in processes such as improving the quality of gasoline, developing polymers and synthesizing pharmaceuticals.

16 Nov 2004

New software for the investigation of cancer

NorayBio, a bioinformatics company located at the Bizkaia Technological Park (Basque Country) and specialising in developing software for the biosciences, has launched a new software for cancer research on to the market - BITIA, primarily aimed at research centres and cancer wards in hospitals.

16 Nov 2004

Hearing set to determine if the U.S. will be better prepared for next year’s flu season

U.S. Senator Larry Craig Larry Craig has announced today that the U.S. Senate Special Committee on Aging will hold a hearing on Tuesday, November 16, 2004 at 2:30 p.m. titled “Liability, Licensing and the Flu Vaccine Market: Making Decisions Today to Prevent a Crisis Tomorrow.” It will be held in room 562.

14 Nov 2004

Scientists and clinicians are pioneering the diagnosis and treatment of children's brain tumours

The University of Birmingham, England, is working with Birmingham Children's Hospital to use high-tech science to make a difference to children's lives.

11 Nov 2004

All patients in study clear parasite that causes African sleeping sickness

Immtech International has announced that all 30 patients participating in the concluded Phase IIb extended dose regimen arm of its clinical trial of DB289 for treating African sleeping sickness cleared the parasite that causes African sleeping sickness within the treatment period, with no significant adverse results reported.

11 Nov 2004

Shp2 protein plays a critical role in obesity

A team of researchers led by The Burnham Institute's Gen-Sheng Feng, Ph.D. has discovered that a protein called Shp2 plays a critical role in obesity.

11 Nov 2004

Dementia patients receiving long-term treatment with Reminyl may be able to stay at home for longer compared

Shire Pharmaceuticals Group has announced that Dementia patients receiving long-term treatment with Reminyl (more than 36 months) may be able to stay at home for longer compared to those receiving treatment for shorter periods of time.

10 Nov 2004

Obesity statistics are as bogus as weight-loss scams

The weight-loss industry is finding itself in the crosshairs of the Federal Trade Commission's "Operation Big Fat Lies" -- a crackdown on slimming down pills, powders and patches that are too good to be true. The Center for Consumer Freedom (CCF) recommends that grossly exaggerated statistics and hype from pharmaceutical and weight-loss companies about the nation's so-called "obesity epidemic" also be placed under the federal microscope.

10 Nov 2004

Merck licenses new and improved methods for developing antibiotics from San Diego State University

Two new and improved methods of developing antibiotics discovered at San Diego State University have been licensed to Merck Pharmaceuticals for $300,000, the largest technology transfer agreement so far for SDSU.

9 Nov 2004